Canaccord Genuity Sticks to Its Buy Rating for AdaptHealth (AHCO)
Canaccord Genuity analyst Richard Close maintained a Buy rating on AdaptHealth today and set a price target of $15.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Close is a 4-star analyst with an average return of 10.1% and a 48.34% success rate. Close covers the Healthcare sector, focusing on stocks such as Clover Health Investments, Phreesia, and Premier.
In addition to Canaccord Genuity, AdaptHealth also received a Buy from Truist Financial’s David S Macdonald in a report issued yesterday. However, on the same day, TR | OpenAI – 4o downgraded AdaptHealth (NASDAQ: AHCO) to a Hold.
Based on AdaptHealth’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $820.31 million and a net profit of $24.51 million. In comparison, last year the company earned a revenue of $805.86 million and had a net profit of $22.86 million
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AHCO in relation to earlier this year.
Read More on AHCO:
